A medication already prescribed to millions of people for type 2 diabetes and obesity may one day help treat cocaine addiction.
In a new study from the University of Gothenburg in Sweden, researchers found that semaglutide, commonly sold under the brand names Ozempic and Wegovy, reduced cocaine use, relapse-like behavior, and the motivation to seek the drug in laboratory rats.
The findings, published in European Neuropsychopharmacology, show that rats trained to self-administer cocaine reduced their intake by an average of 26 percent when given semaglutide. Relapse-like behavior fell by 62 percent, and motivation to pursue the drug dropped by 52 percent.
Scientists believe semaglutide may interfere with cocaines ability to raise dopamine levels in the brain, lowering the sense of reward, though the exact mechanism remains unclear.
“Our results show that an established drug can affect key behaviors behind cocaine addiction. We hope this could open the way for new treatments, but clinical trials are needed before we know if the same effect is seen in patients,” said lead author Cajsa Aranäs, a researcher at the Sahlgrenska Academy, University of Gothenburg.
While several GLP-1 receptor drugs are already approved for diabetes and weight management worldwide, semaglutide is the most widely known. Researchers stress that human trials are needed before the drug could be considered for clinical use in treating cocaine addiction.
“There is a pressing demand for treatments for cocaine addiction. Currently, no drugs are available, and the risk of relapse is very high,” said Elisabet Jerlhag, Professor of Pharmacology at the Sahlgrenska Academy, who led the study. “If these findings in rats hold up in clinical trials, semaglutide could become the first pharmacological option to complement psychological therapy and support programs.”